Rigel Pharmaceuticals Files Proxy Statement Addendum
Ticker: RIGL · Form: DEFA14A · Filed: Apr 10, 2024 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | DEFA14A |
| Filed Date | Apr 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing
Related Tickers: RIGL
TL;DR
Rigel Pharma filed proxy docs, no fee. All good.
AI Summary
Rigel Pharmaceuticals, Inc. filed a Definitive Additional Materials (DEFA14A) on April 10, 2024. This filing is related to their proxy statement and indicates no fee was required for this submission. The company is based in South San Francisco, California.
Why It Matters
This filing is a routine update to Rigel Pharmaceuticals' proxy statement, providing additional materials for shareholders ahead of any upcoming meetings or votes.
Risk Assessment
Risk Level: low — This filing is a standard proxy statement amendment and does not contain new material information that would inherently increase risk.
Key Players & Entities
- RIGEL PHARMACEUTICALS, INC. (company) — Registrant
- 0001034842 (company) — Central Index Key
- 650-624-1100 (company) — Business Phone
FAQ
What type of filing is this DEFA14A for Rigel Pharmaceuticals?
This filing is for Definitive Additional Materials related to a proxy statement.
When was this filing submitted to the SEC?
The filing was submitted on April 10, 2024.
Is there a filing fee associated with this DEFA14A?
No fee was required for this filing.
Where is Rigel Pharmaceuticals, Inc. headquartered?
Rigel Pharmaceuticals, Inc. is located at 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.
What is the standard industrial classification for Rigel Pharmaceuticals?
The standard industrial classification is Pharmaceutical Preparations [2834].
Filing Stats: 125 words · 1 min read · ~1 pages · Grade level 12.4 · Accepted 2024-04-10 16:50:34
Filing Documents
- ny20018910x3_defa14a.htm (DEFA14A) — 12KB
- ny20018910x3_na1.jpg (GRAPHIC) — 296KB
- ny20018910x3_na2.jpg (GRAPHIC) — 428KB
- 0001140361-24-019134.txt ( ) — 1010KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 RIGEL PHARMACEUTICALS, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.